AC Immune SA
NASDAQ:ACIU
3.11 (USD) • At close October 22, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 14.801 | 3.935 | 0 | 15.431 | 111.026 | 7.194 | 20.255 | 23.214 | 39.09 | 30.269 | 8.637 |
| Cost of Revenue
| 54.606 | 60.336 | 62.282 | 59.487 | 50.432 | 44.277 | 32.663 | 25.774 | 17.049 | 16.116 | 17.18 |
| Gross Profit
| -39.805 | -56.401 | -62.282 | -44.056 | 60.594 | -37.083 | -12.408 | -2.56 | 22.041 | 14.153 | -8.543 |
| Gross Profit Ratio
| -2.689 | -14.333 | 0 | -2.855 | 0.546 | -5.155 | -0.613 | -0.11 | 0.564 | 0.468 | -0.989 |
| Reseach & Development Expenses
| 54.606 | 60.336 | 62.282 | 59.487 | 50.432 | 44.277 | 32.663 | 25.774 | 17.049 | 16.116 | 17.18 |
| General & Administrative Expenses
| 10.576 | 15.789 | 10.879 | 11.086 | 9.421 | 7.564 | 6.274 | 4.728 | 2.04 | 1.999 | 2.955 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 10.576 | 15.789 | 10.879 | 11.086 | 9.421 | 7.564 | 6.274 | 4.728 | 2.04 | 1.999 | 2.955 |
| Other Expenses
| 3.243 | -1.343 | 5.849 | 6.118 | 6.637 | 4.903 | 3.857 | 3.168 | 1.377 | 1.437 | 0 |
| Operating Expenses
| 68.425 | 74.782 | 79.01 | 76.691 | 66.49 | 56.744 | 42.794 | 33.67 | 20.466 | 19.552 | 2.758 |
| Operating Income
| -53.624 | -70.847 | -79.01 | -61.26 | 44.536 | -49.55 | -22.539 | -10.456 | 18.624 | 10.717 | -11.498 |
| Operating Income Ratio
| -3.623 | -18.004 | 0 | -3.97 | 0.401 | -6.888 | -1.113 | -0.45 | 0.476 | 0.354 | -1.331 |
| Total Other Income Expenses Net
| -1.467 | 0.107 | 6.017 | -0.661 | 0.906 | -1.194 | -4.049 | 3.36 | 1.617 | 0.027 | 0.255 |
| Income Before Tax
| -54.223 | -70.74 | -72.993 | -61.921 | 45.442 | -50.951 | -26.411 | -7.096 | 20.27 | 10.744 | -11.243 |
| Income Before Tax Ratio
| -3.663 | -17.977 | 0 | -4.013 | 0.409 | -7.082 | -1.304 | -0.306 | 0.519 | 0.355 | -1.302 |
| Income Tax Expense
| 0.01 | 0.013 | 0.003 | 0.184 | 1.894 | -1.103 | 0.147 | 3.616 | 1.643 | 0.031 | 0 |
| Net Income
| -54.233 | -70.753 | -72.996 | -62.105 | 45.442 | -50.951 | -26.411 | -7.096 | 20.27 | 10.744 | -11.243 |
| Net Income Ratio
| -3.664 | -17.98 | 0 | -4.025 | 0.409 | -7.082 | -1.304 | -0.306 | 0.519 | 0.355 | -1.302 |
| EPS
| -0.64 | -0.85 | -0.97 | -0.86 | 0.64 | -0.82 | -0.46 | -0.14 | 0.37 | 0.19 | -0.28 |
| EPS Diluted
| -0.64 | -0.85 | -0.97 | -0.86 | 0.64 | -0.82 | -0.46 | -0.14 | 0.37 | 0.19 | -0.28 |
| EBITDA
| -50.365 | -70.778 | -70.119 | -59.215 | 46.501 | -48.498 | -21.635 | -6.562 | 20.583 | 11.046 | -11.205 |
| EBITDA Ratio
| -3.403 | -17.987 | 0 | -3.837 | 0.419 | -6.741 | -1.068 | -0.283 | 0.527 | 0.365 | -1.297 |